LS mean percent change from baseline to Day 84 in Low-Density Lipoprotein Cholesterol (LDL-C) in the obicetrapib group compared to the placebo group [PUC]. LDL-C level was measured by preparative ultracentrifugation (PUC).

Baseline Population is defined as all participants who were randomized in the study. Baseline values were defined as last measurement prior to the first dose of study drug. 2 participants in the obi arm were randomized but did not receive study drug, therefore the "n" for the obi arm baseline values did not exceed n=234. In addition, participants needed available labs at both baseline and Day 84.

LS mean percent change from baseline to Day 180 in Low-Density Lipoprotein Cholesterol (LDL-C) in the obicetrapib group compared to the placebo group [Martin/Hopkins]. LDL-C value was calculated using the Martin/Hopkins equation unless TG >= 400 mg/dL or LDL-C <= 50 mg/dL; where, LDL-C value was measured directly by preparative ultracentrifugation (PUC).

Baseline Population is defined as all participants who were randomized in the study. Baseline values were defined as last measurement prior to the first dose of study drug. 2 participants in the obi arm were randomized but did not receive study drug, therefore the "n" for the obi arm baseline values did not exceed n=234. In addition, participants needed available labs at both baseline and Day 180.

LS mean percent change from baseline to Day 365 in Low-Density Lipoprotein Cholesterol (LDL-C) in the obicetrapib group compared to the placebo group [PUC]. LDL-C level was measured by preparative ultracentrifugation (PUC).

Baseline Population is defined as all participants who were randomized in the study. Baseline values were defined as last measurement prior to the first dose of study drug. 2 participants in the obi arm were randomized but did not receive study drug, therefore the "n" for the obi arm baseline values did not exceed n=234. In addition, participants needed available labs at both baseline and Day 365.

LS mean percent change from baseline to Day 84 in apolipoprotein B (ApoB) in obicetrapib group compared to the placebo group.

Baseline Population is defined as all participants who were randomized in the study. Baseline values were defined as last measurement prior to the first dose of study drug. 2 participants in the obi arm were randomized but did not receive study drug, therefore the "n" for the obi arm baseline values did not exceed n=234. In addition, participants needed available labs at both baseline and Day 84.

LS mean percent change from baseline to Day 180 in apolipoprotein B (ApoB) in obicetrapib group compared to the placebo group

Baseline Population is defined as all participants who were randomized in the study. Baseline values were defined as last measurement prior to the first dose of study drug. 2 participants in the obi arm were randomized but did not receive study drug, therefore the "n" for the obi arm baseline values did not exceed n=234. In addition, participants needed available labs at both baseline and Day 180.

LS mean percent change from baseline to Day 365 in apolipoprotein B (ApoB) in obicetrapib group compared to the placebo group

Baseline Population is defined as all participants who were randomized in the study. Baseline values were defined as last measurement prior to the first dose of study drug. 2 participants in the obi arm were randomized but did not receive study drug, therefore the "n" for the obi arm baseline values did not exceed n=234. In addition, participants needed available labs at both baseline and Day 365.

LS mean percent change from baseline to Day 84 in Non-high-density Lipoprotein Cholesterol (Non-HDL-C) in obicetrapib group compared to the placebo group

Baseline Population is defined as all participants who were randomized in the study. Baseline values were defined as last measurement prior to the first dose of study drug. 2 participants in the obi arm were randomized but did not receive study drug, therefore the "n" for the obi arm baseline values did not exceed n=234. In addition, participants needed available labs at both baseline and Day 84.

LS mean percent change from baseline to Day 180 in Non-high-density Lipoprotein Cholesterol (non-HDL-C) in obicetrapib group compared to the placebo group

Baseline Population is defined as all participants who were randomized in the study. Baseline values were defined as last measurement prior to the first dose of study drug. 2 participants in the obi arm were randomized but did not receive study drug, therefore the "n" for the obi arm baseline values did not exceed n=234. In addition, participants needed available labs at both baseline and Day 180.

LS mean percent change from baseline to Day 365 in Non-high-density Lipoprotein Cholesterol (non-HDL-C) in obicetrapib group compared to the placebo group

Baseline Population is defined as all participants who were randomized in the study. Baseline values were defined as last measurement prior to the first dose of study drug. 2 participants in the obi arm were randomized but did not receive study drug, therefore the "n" for the obi arm baseline values did not exceed n=234. In addition, participants needed available labs at both baseline and Day 365.

LS mean percent change from baseline to Day 84 in High-density Lipoprotein Cholesterol (HDL-C) in obicetrapib group compared to the placebo group

Baseline Population is defined as all participants who were randomized in the study. Baseline values were defined as last measurement prior to the first dose of study drug. 2 participants in the obi arm were randomized but did not receive study drug, therefore the "n" for the obi arm baseline values did not exceed n=234. In addition, participants needed available labs at both baseline and Day 84.

LS mean percent change from baseline to Day 180 in High-density Lipoprotein Cholesterol (HDL-C) in obicetrapib group compared to the placebo group

Baseline Population is defined as all participants who were randomized in the study. Baseline values were defined as last measurement prior to the first dose of study drug. 2 participants in the obi arm were randomized but did not receive study drug, therefore the "n" for the obi arm baseline values did not exceed n=234. In addition, participants needed available labs at both baseline and Day 180.

LS mean percent change from baseline to Day 365 in High-density Lipoprotein Cholesterol (HDL-C) in obicetrapib group compared to the placebo group

Baseline Population is defined as all participants who were randomized in the study. Baseline values were defined as last measurement prior to the first dose of study drug. 2 participants in the obi arm were randomized but did not receive study drug, therefore the "n" for the obi arm baseline values did not exceed n=234. In addition, participants needed available labs at both baseline and Day 365.

LS mean percent change from baseline to Day 84 in Lipoprotein (a) [Lp(a)] in obicetrapib group compared to the placebo group

Baseline Population is defined as all participants who were randomized in the study. Baseline values were defined as last measurement prior to the first dose of study drug. 2 participants in the obi arm were randomized but did not receive study drug, therefore the "n" for the obi arm baseline values did not exceed n=234. In addition, participants needed available labs at both baseline and Day 84.

LS mean percent change from baseline to Day 365 in Lipoprotein (a) [Lp(a)] in obicetrapib group compared to the placebo group

Baseline Population is defined as all participants who were randomized in the study. Baseline values were defined as last measurement prior to the first dose of study drug. 2 participants in the obi arm were randomized but did not receive study drug, therefore the "n" for the obi arm baseline values did not exceed n=234. In addition, participants needed available labs at both baseline and Day 365.

LS mean percent change from baseline to Day 84 in Total Cholesterol (TC) in obicetrapib group compared to the placebo group

Baseline Population is defined as all participants who were randomized in the study. Baseline values were defined as last measurement prior to the first dose of study drug. 2 participants in the obi arm were randomized but did not receive study drug, therefore the "n" for the obi arm baseline values did not exceed n=234. In addition, participants needed available labs at both baseline and Day 84.

LS mean percent change from baseline to Day 180 in Total Cholesterol in obicetrapib group compared to the placebo group

Baseline Population is defined as all participants who were randomized in the study. Baseline values were defined as last measurement prior to the first dose of study drug. 2 participants in the obi arm were randomized but did not receive study drug, therefore the "n" for the obi arm baseline values did not exceed n=234. In addition, participants needed available labs at both baseline and Day 180.

LS mean percent change from baseline to Day 365 in Total Cholesterol in obicetrapib group compared to the placebo group

Baseline Population is defined as all participants who were randomized in the study. Baseline values were defined as last measurement prior to the first dose of study drug. 2 participants in the obi arm were randomized but did not receive study drug, therefore the "n" for the obi arm baseline values did not exceed n=234. In addition, participants needed available labs at both baseline and Day 365.

LS mean percent change from baseline to Day 84 in Triglycerides in obicetrapib group compared to the placebo group

Baseline Population is defined as all participants who were randomized in the study. Baseline values were defined as last measurement prior to the first dose of study drug. 2 participants in the obi arm were randomized but did not receive study drug, therefore the "n" for the obi arm baseline values did not exceed n=234. In addition, participants needed available labs at both baseline and Day 84.

LS mean percent change from baseline to Day 180 in Triglycerides in obicetrapib group compared to the placebo group

Baseline Population is defined as all participants who were randomized in the study. Baseline values were defined as last measurement prior to the first dose of study drug. 2 participants in the obi arm were randomized but did not receive study drug, therefore the "n" for the obi arm baseline values did not exceed n=234. In addition, participants needed available labs at both baseline and Day 180.

LS mean percent change from baseline to Day 365 in Triglycerides in obicetrapib group compared to the placebo group

Baseline Population is defined as all participants who were randomized in the study. Baseline values were defined as last measurement prior to the first dose of study drug. 2 participants in the obi arm were randomized but did not receive study drug, therefore the "n" for the obi arm baseline values did not exceed n=234. In addition, participants needed available labs at both baseline and Day 365.